Precigen Q3 2020 Earnings Report
Key Takeaways
Precigen reported a revenue increase of 29% to $23.6 million and a reduced net loss from continuing operations of $29.5 million, compared to $49.1 million in the third quarter of 2019. The company highlighted progress in its clinical pipeline, including the dosing of the first patient in the PRGN-2009 Phase I/II trial and advancements in the UltraPorator system.
Total revenues increased by 29% to $23.6 million compared to Q3 2019.
Net loss from continuing operations decreased to $29.5 million, an improvement from $49.1 million in Q3 2019.
The first patient was dosed in the Phase I/II trial for PRGN-2009 AdenoVerseâ„¢ Immunotherapy.
Precigen's UltraPorator system was cleared by the FDA as a manufacturing device for its UltraCAR-T manufacturing process.
Precigen
Precigen
Precigen Revenue by Segment
Revenue & Expenses
Visualization of income flow from segment revenue to net income